New insights into the activities and toxicities of the old anticancer drug doxorubicin

• Published in: The FEBS journal Vol. 288; no. 21; pp. 6095 - 6111
• Main Authors: van der Zanden, Sabina Y., Qiao, Xiaohang, Neefjes, Jacques
• Format: Journal Article
• Language: English
• Published: Oxford Blackwell Publishing Ltd 01.11.2021; John Wiley and Sons Inc
• Subjects: aclarubicin; Anthracycline; anthracyclines; Anticancer properties; Antitumor agents; Cancer; Cardiotoxicity; Chemical separation; Chromatin; chromatin damage; Damage; Deoxyribonucleic acid; DNA; DNA damage; DNA topoisomerase (ATP-hydrolysing); Doxorubicin; genome; Genomes; histone eviction; Histones; Quality of life; separation; Side effects; Solid tumors; State‐of‐the‐Art Review; State‐of‐the‐Art Reviews; therapy‐related tumours; topoisomerase II; Toxicity; Tumors

The anthracycline drug doxorubicin is an effective anticancer drugs with both DNA‐ and chromatin‐damaging activity. While the chromatin‐damaging activity constitutes major anticancer efficacy of doxorubicin, combination with the DNA‐damaging activity plagues the drug with long‐term toxicities such a...